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Abstract
Background: The CXC chemokine, CXCL12, and its receptor, CXCR4 promote metastases of
a variety of solid tumors, including non-small cell lung cancer (NSCLC). The expression of CXCR4
on tumor cells may represent a critical biomarker for their propensity to metastasize. This study
was performed to evaluate the hypothesis that co-expression of pan-cytokeratin and CXCR4 may
be a prognostic marker for patients with advanced NSCLC.
Methods: We evaluated CXCR4 levels on circulating pan-cytokeratin positive cells from patients
with NSCLC. NSCLC tumor and metastases were also assessed for the presence of CXCR4.
Results: Pan-cytokeratin positive cells were increased in the circulation of patients with NSCLC,
as compared to normal control subjects. Patients with pan-cytokeratin +/CXCR4+ = 2,500 cells/
ml had a significant improvement in median survival when compared with patients with pan-
cytokeratin +/CXCR4+ >2,500 cells/ml (not achieved versus 14 weeks). CXCR4 expression was
found on NSCLC tumors and at sites of tumor metastasis.
Conclusion:  This study suggests that CXCR4 may be a prognostic marker in NSCLC, and
provides hypothesis-generating results, which may be important in determining metastatic
potential. In future studies, we will prospectively evaluate the prognostic significance of pan-
cytokeratin/CXCR4+ cells, and determine the mechanisms involved in the regulation of CXCR4
expression on tumor cells in a larger patient population.
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Background
Approximately 213,380 new cases of lung cancer will be
diagnosed and 160,390 deaths will occur from lung can-
cer during 2007. Lung cancer is the leading cause of cancer
death among both men and women in the United States
[1]. Nearly 60% of those diagnosed with lung cancer die
within one year of their diagnosis, and the five-year sur-
vival for all patients with lung cancer is only 16%. This sta-
tistic has not improved significantly in the past 10 years.
Surgical resection offers the most promising chance for
cure in patients who present with early-stage disease,
although the majority of patients will develop recurrence
despite complete surgical resection. This is likely second-
ary to undetected microscopic metastatic disease at the
time of surgery, and recently adjuvant chemotherapy has
been shown to improve survival in some early-stage
patients [2-4]. Identification of targeted treatments for
micrometastatic disease could block tumor cell migration
and improve outcomes in this devastating disease.
Cytokeratins have been identified as potential markers for
the detection of circulating cancer cells by RT-PCR, flow
cytometry and RT-PCR [5-7]. Cytokeratin 19 has been
described in the serum of patients with non-small cell
lung cancer (NSCLC), and has been associated with tumor
burden and response to therapy [7,8]. However, cytok-
eratins can be expressed in low levels in peripheral blood
mononuclear cells, which limits the utility of this biomar-
ker to accurately detect circulating micrometastatic dis-
ease.
Chemokines within the tumor microenvironment, and at
sites of metastases can mediate invasion of tumor cells
through mechanisms similar to those used in leukocyte
stem cell trafficking [9]. Chemokines are a family of 8–11
kd proteins, subdivided on the basis of the position of the
N-terminus cysteine residues. They are involved in leuko-
cyte chemotaxis and activation, and have been associated
with the regulation of angiogenesis and tumor cell inva-
sion [10-12]. Chemokine receptors are seven transmem-
brane, G protein-coupled receptors, and are expressed on
leukocytes, endothelial cells, stromal cells, epithelial cells
and tumor cells [13,14]. Chemokine gradients within the
tumor microenvironment and target organs can deter-
mine the metastatic potential of a tumor [15].
CXCR4 has been the major chemokine receptor expressed
on cancer cells [16-20]. Its ligand, CXCL12 is essential for
the homing of hematopoeitic stem cells during embryo-
genesis and adult life [21,22]. Müller and colleagues pro-
vided initial evidence linking CXCL12/CXCR4 biological
axis to breast cancer metastasis to specific organs [16],
which was confirmed in non-small lung cancer [20]. More
recent studies have suggested that CXCR4 is expressed on
various other cancer cells and its expression stimulated
migration of cancer cells towards a CXCL12 gradient
established in specific target organs for metastases [17-
19]. The CXCR4/CXCL12 biological axis has been postu-
lated to have an important in supporting cancer stem cells
[23]. These findings suggest that CXCL12/CXCR4 may be
a critical determinant for the metastatic potential of
NSCLC, and supports the notion that the magnitude of
pan-cytokeratin+ circulating cells that express CXCR4 will
correlate with survival of patients with NSCLC. In this
study we tested this hypothesis and found that the magni-
tude of circulating pan-cytokeratin+/CXCR4+ cells in
patients with NSCLC was directly correlated with worse
prognosis, and that these findings could be used as a foun-
dation for future prospective biomarker studies. Further-
more, these results support the contention that further
understanding the molecular mechanisms that are
involved in the regulation of CXCR4 expression on tumor
cells could lead to potential targets to modify the expres-
sion of CXCR4 on NSCLC cells and impact on metastases.
Methods
Study Design
Sixteen subjects with NSCLC and 10 normal healthy
donors seen at UCLA Medical Center between October
2004 and March 2006 were enrolled. The UCLA institu-
tional review board approved this study protocol, and all
patients provided written informed consent. Peripheral
blood was collected from patients prior to initiating sys-
temic therapy.
FACS analysis
Each specimen was processed to isolate buffy coat leuko-
cyte populations for intracellular staining and FACS anal-
ysis. Briefly, buffy coat was isolated, red blood cells lysed,
and the cells stained with APC anti-CXCR4 (R&D systems,
Minneapolis, MN) or isotype control. Cells were then per-
meabilized with a BD Cytofix/Cytoperm kit (BD Bio-
sciences) and stained with PE anti-Pan-cytokeratin (BD
Biosciences). Samples were analyzed on a FACSCalibur
instrument using Cellquest 3.2.1f1 software (BD Bio-
sciences).
Immunohistochemistry
Paraffin-embedded tissue microarrays (Lung: cancer-
metastasis-normal) were purchased from Imgenex Corp.
(San Diego, CA). The arrays were processed for immuno-
histochemical localization of CXCR4, using monoclonal
anti-human CXCR4 antibodies or IgG2b antibodies for
negative control (R&D Systems) as using Vector Elite Kit
(Vector Laboratories, Burlingame, California, USA) as
described previously [24]. Briefly, the tissue array was
incubated with a 1:1 mixture of 3% hydrogen peroxide in
methanol. The array was then exposed to Power Block
(BioGenex Laboratories, San Ramon, California, USA) for
30 minutes and, after washing in PBS, stained withBMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
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CXCR4 antibodies or an isotype control antibody for 30
minutes at room temperature. After incubation with the
primary Ab, the array was then exposed to a biotinylated
anti-mouse secondary Ab for 30 minutes. The array was
washed in PBS and avidin-binding complex (Vector Labo-
ratories) reagent was added, and the array incubated again
for 30 minutes. The array was then exposed to the chro-
mogen 3,3'-diaminobenzidine tetrahydrochloride (Vector
Laboratories), which turns the positively staining cells
brown. Finally, the array was counterstained with hema-
toxylin and cover-slipped.
Statistical Analysis
Data were analyzed on a Dell PC computer using SAS ver-
sion 9.2 XP_PRO platform. Non parametric Kruskal-Wal-
lis test was used to detect the group differences because of
small sample size. A survival curve was estimated accord-
ing to the Kaplan-Meier method and groups compared
with the log rank test. A p-value = 0.05 was considered sig-
nificant.
Results
CXCR4 is Markedly Expressed on NSCLC Primary Tumor 
and in Cells of Metastatic Lesions from NSCLC tissue 
microarrays
Immunostaining for CXCR4 expression on these NSCLC
tissue microarrays confirmed significant expression of
CXCR4 on both tumor cells of primary tumors (Figure 1A
and 1B) and metastatic lesions (Figure 1D and 1E).
CXCR4 is expressed on a majority (>80%) of the tumor
cells in either adenocarcinoma or squamous cell carci-
noma lung tumor specimens (Figure 1A and 1B, respec-
tively). All of the squamous cell carcinoma or
adenocarcinoma lung tumor specimens examined
CXCR4 expression on both tumor cells of primary tumors and metastatic lesions Figure 1
CXCR4 expression on both tumor cells of primary tumors and metastatic lesions. A) adenocarcinoma, B) squa-
mous cell carcinoma, C) adenocarcinoma (negative control), D) lymph node metastasis, E) bone metastasis, and F) bone metas-
tasis (negative control). Magnification is at 100× for A-C and 200× for D-F.BMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
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expressed positive staining for CXCR4. There was no evi-
dence for non-specific staining with the control antibody
(Figure 1C and 1F). In addition, there was little evidence
of CXCR4 immunolocalization on host responding cells,
such as tumor-associated macrophages, fibroblasts and
endothelial cells (Figure 1). Moreover, we found that the
expression of CXCR4 was a significant biomarker of met-
astatic NSCLC in various tissues (Figure 1D and 1E). In
contrast, we found no difference in protein levels of
CXCL12 in NSCLC tumors (squamous cell carcinoma and
adenocarcinoma), as compared to normal lung tissue
(data not shown).
CXCR4 Expression and Pan-cytokeratin levels are 
Elevated in Blood of Patients with NSCLC
Patient Characteristics
Sixteen patients with NSCLC were enrolled to this study
for the analysis of CXCR4 and pan-cytokeratin expression
on circulating tumor cells. Eight females and eight males
with an average age of 69 years were studied. Two patients
had stage IA NSCLC, one had stage IIIA, one had stage IIIB
and twelve had stage IV disease. Fourteen patients had
been previously untreated and 2 subjects received 1 prior
systemic treatment for metastatic disease. Only 2 patients
had never smoked in this group (Table 1). The median
survival for the group was 60 weeks, (range 6-not
reached).
Table 1: Patient Characteristics
All patients
(N = 16)
Low risk group
(CXCR4 ≤ 2500 cells/ml)
(n = 11)
High risk group
(CXCR4 > 2500 cells/ml)
(n = 5)
Gender
F8 5 3
M8 6 2
Age
Mean ± SD 69 ± 10 67 ± 11 74 ± 6
Min-max, median 42–83, 73 42–79, 70 67–83, 73
Stage
IA 2 2 0
IIIA 1 0 1
IIIB 1 1 0
IV 12 8 4
ECOG PS
01 0 7 3
16 4 2
Histology
Adenocarcinoma 6 4 2
Large cell 1 0 1
Squamous cell 2 1 1
Not Specified 7 6 1
Tobacco (pack-years)
02 2 0
1–20 4 3 1
>20 10 6 4
# of prior treatments
01 4 9 5
12 2 0
Mean Survival (weeks) 65 ± 50 79 ± 46 34 ± 50
Median Survival (weeks) 60 (6-NA) NA (15-NA) 14 (6-NA)*
NA, not achieved
*p = 0.03 and hazard ratio of 0.23 (95% CI, 0.02–0.79) for median survival of low risk group versus high risk group (log-rank test).BMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
Page 5 of 9
(page number not for citation purposes)
CXCR4 and Pan-cytokeratin Expression in Peripheral Blood
We hypothesized that CXCR4 and cytokeratin would be
increased on circulating cells of patients with NSCLC. To
determine CXCR4 expression on mononuclear cells
expressing pan-cytokeratin, we measured human cytoker-
atin 14, 15, 16, and 19 (pan-cytokeratin) along with
CXCR4 on peripheral blood mononuclear cells (PBMC)
by FACS in 16 NSCLC patients and 10 normal controls.
CXCR4 and pan-cytokeratin expression was elevated on
circulating cells of patients with NSCLC. We found pan-
cytokeratin expression was significantly increased (p =
0.02) on PBMC of patients with NSCLC when compared
to normal controls (Figure 2). Combined pan-cytokera-
tin/CXCR4 expression was increased in patients with
NSCLC, but the result was not significant (p = 0.11).
Low Circulating CXCR4 and Pan-cytokeratin Expression Predicts for 
Improved Survival
CXCR4 was elevated on circulating pan-cytokeratin posi-
tive cells in sixteen patients with NSCLC (Figure 3). In
these patients, we evaluated survival based on co-expres-
sion of pan-cytokeratin and CXCR4. Using a cut point of
2500 CXCR4 positive cells/ml, we found a significant
improvement in overall survival for patients with low cir-
culating pan-cytokeratin/CXCR4-positive cells when com-
pared to patients with high levels of circulating pan-
cytokeratin/CXCR4-positive cells (p = 0.03) (Table 1).
Circulating pan-cytokeratin positive cells and CXCR4/pan-cytokeratin positive cells in 16 patients with NSCLC and 10 normal  subjects Figure 2
Circulating pan-cytokeratin positive cells and CXCR4/pan-cytokeratin positive cells in 16 patients with NSCLC 
and 10 normal subjects. CXCR4 and pan-cytokeratin were measured by FACS from normal healthy donors or patients with 
NSCLC (*p = 0.11, **p = 0.02). Horizontal line represents mean.BMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
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Despite the small sample size, the hazard ratio for survival
in the group with low expression of pan-cytokeratin/
CXCR4-positive cells was 0.23 (95% confidence interval
(CI), 0.02–0.79). The median overall survival (OS) for
patients with NSCLC who had low levels of CXCR4
expression on MNC (≤ 2500 CXCR4 positive cells/ml)
was not reached versus a median OS of 14 weeks for those
with a CXCR4 expression level > 2500 CXCR4 positive
cells/ml (Figure 4).
Discussion
The microenvironment and receptor signaling of the
tumor plays a role in promoting the expression of genes
that may be relevant in promoting tumor metastases.
Chemokines are a group of homologous, yet functionally
pleiotropic proteins that directly mediate cell migration
and activation and play a role in regulating angiogenesis
and metastases [25]. The CXC chemokine, CXCL12, and
its receptor, CXCR4 promote metastases of a variety of
solid tumors including non-small cell lung cancer
(NSCLC) [9,16,20,26]. In a human NSCLC SCID mouse
chimera, neoplastic cells at secondary metastatic sites sig-
nificantly upregulate CXCR4 [26]. Furthermore, CXCL12,
the ligand for CXCR4, has been shown to be maximally
expressed in the organs of metastasis in both lung and
breast cancers [9,16]. This concept supports the notion
that expression of CXCR4 on tumor cells may represent a
critical biomarker for their propensity to metastasize. This
study was performed to evaluate the hypothesis that
CXCR4 may be a marker for circulating tumor cells in met-
astatic NSCLC.
CXCR4 may play a role in the transition of a tumor from
non-metastatic to its malignant phenotype [27]. In this
study, we demonstrated that CXCR4 is expressed on pri-
mary lung tumors as well as metastatic lesions. This is
consistent with previous findings that elevated levels of
CXCR4 expression in NSCLC tumors was associated with
clinical metastases [28]. Moreover, CXCR4 expression in
squamous cell carcinoma of the head and neck could be
used to identify tumor cells with increased metastatic
potential [29]. Thus, identifying cells with increased
CXCR4 expression may be useful to predict the metastatic
potential of a tumor and provides a mechanism for inhib-
iting tumor progression.
CXCR4 expression on circulating pan-cytokeratin positive cells in patients with NSCLC Figure 3
CXCR4 expression on circulating pan-cytokeratin positive cells in patients with NSCLC. Individual patient data for 
CXCR4 and pan-cytokeratin–these were measured by FACS from normal healthy donors (NL) or patients with NSCLC (CA). 
Results from six representative normal healthy donors are provided.BMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
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We also demonstrate that circulating pan-cytokeratin and
CXCR4 positive cells are more prevalent in patients with
NSCLC than normal subjects. Circulating pan-cytokeratin
cells were significantly elevated in NSCLC patient when
compared to normal subjects. When evaluating pan-
cytokeratin and CXCR4 positive together, we saw a trend
toward increased levels of CXCR4 expression in NSCLC
patients, but this was not statistically significant. The rea-
sons for this observation may be due to our limited sam-
ple size since the pool of circulating CXCR4 positive cells
may represent cancer stem cells[9] and comprise a smaller
proportion of the cells. Similar findings have been
described in metastatic renal cell carcinoma (RCC). Pan,
et al. demonstrated that CXCR4 expression was markedly
increased on circulating pan-cytokeratin+ cells of patients
with metastatic RCC, as compared to normal control sub-
jects, suggesting that these cells were comparable with cir-
culating malignant cells [30]. CXCR4 was the
predominant biomarker on pan-cytokeratin+ cells in the
circulation of patients with metastatic RCC, suggesting
that the presence of CXCR4 expression on these cells may
directly correlate with metastatic RCC. Furthermore, we
found that elevated co-expression of pan-cytokeratin and
CXCR4 may be a prognostic marker for patients with
advanced disease, as most patients in this study had stage
III or IV lung cancer. Elevated co-expression of pan-cytok-
eratin and CXCR4 was significantly associated with poor
survival in NSCLC.
CXCR4 may be important in our search to identify a
biomarker or group of markers that offer the ability to
detect micrometastatic disease in the blood before sys-
temic recurrence or progression. A wide variety of biomar-
kers have been studied to this end, and implicated in
determining prognosis for NSCLC. Thyroid transcription
factor 1 (TTF1) is responsible for regulating gene tran-
scription in the organogenesis of both thyroid and lung
[31]. It has been an important marker in identifying pri-
mary lung cancers. TTF1 has been described as a potential
prognostic marker associated with improved survival for
patients with stage I adenocarcinoma of the lung [32].
Epithelial cellular adhesion molecule (Ep-CAM) has also
been used to ascertain disseminated tumor cells in
patients with surgically resectable NSCLC, and circulating
levels have been associated with reduced disease-free sur-
vival [33,34]. A recent study by Zhu et al developed
immunomarker-support vector machines-based prognos-
tic classifiers for stage IB NSCLC, which were associated
with survival [35]. The models integrate age, cancer cell
type and either 5 or 19 markers including, CD34MVD,
p21ras, p21WAF, BCL2, caspase-9, low-molecular-weight
cytokeratin, high-molecular-weight cytokeratin, cyclooxy-
genase-2, EMA, HER2, matrix metalloproteinases (MMP)-
2, MMP-9, p16, p27kip1, p53, vascular endothelial growth
factor, β- catenin, and tissue inhibitors of metalloproteinases
(TIMP)-1 and TIMP-2. In another study, Nagrath et al
identified a highly sensitive method to evaluate circulat-
ing tumor cells from blood samples, which may correlate
with tumor response to therapy [36]. Exploring these
markers and techniques may prove beneficial for detect-
ing micrometastatic disease in NSCLC. Exploiting signal-
ing pathways involved with associated markers may be
important for inhibiting micrometastatic disease to
improve outcomes.
The expression of CXCR4 and HIF-1α have been linked in
NSCLC [26]. Hypoxia and more specifically HIF-1α has
been found to be a critical transcription factor for gene
expression of CXCR4 [37-39]. Moreover, VHL can nega-
tively regulate the expression of CXCR4, owing to its
capacity to target HIF-1α for degradation under normoxic
conditions [37,38]. This process may be suppressed under
hypoxic conditions in cells allowing HIF-1α-dependent
induction of CXCR4 expression [37,38,40]. These find-
ings suggest that HIF-1α/VHL may play a significant role
in regulating the expression of CXCR4 on tumor cells, and
further understanding this molecular mechanistic link
between HIF-1α and CXCR4 expression may allow the
discovery of a novel means to intervene and impact on
reducing metastatic NSCLC. SDF-1/CXCL12 is also regu-
lated by HIF-1 in endothelial cells, increasing migration of
circulating CXCR4-positive cells to areas of ischemic tis-
sue. Blocking CXCL12 or CXCR4 inhibited the recruit-
ment of these cells to sites of regenerating tissue [41].
Hypoxia, and particularly HIF-1α, has also been shown to
regulate the expression of CXCR4 in cancer, including
NSCLC [38,40,42,43]. Inhibition of chemokine signaling
pathways with small molecule inhibitors has shown
promise as a therapeutic option for regulating NSCLC
growth and metastasis [26,44-46]. Further understanding
of the mechanisms involved in CXCR4-mediated metasta-
Survival by CXCR4 levels, ≤ 2500 cells/ml (low risk group,  black square) vs. >2500 cells/ml (high risk group, black trian- gle) (*p = 0.03) Figure 4
Survival by CXCR4 levels, ≤ 2500 cells/ml (low risk 
group, black square) vs. >2500 cells/ml (high risk 
group, black triangle) (*p = 0.03).BMC Cancer 2009, 9:213 http://www.biomedcentral.com/1471-2407/9/213
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sis, and their interactions with other pathways important
in NSCLC, may lead to more optimal therapeutic strate-
gies in this disease.
Conclusion
These findings suggest that the CXCL12/CXCR4 biological
axis may be a critical determinant for the metastatic
potential of NSCLC. Therefore, further understanding the
molecular mechanisms that are involved in the regulation
of CXCR4 expression on tumor cells could lead to poten-
tial targets to modify the expression of CXCR4 and impact
on metastases. Blocking these pathways may have a signif-
icant impact on the propensity for NSCLC to invade and
metastasize and therefore, the future of treatment for the
disease. In addition, delineation of how chemokine lig-
ands and receptors modulate the malignant phenotype
will provide novel insights into the pathogenesis of lung
carcinoma. These results are not definitive, but hypothe-
sis-generating. In future studies, we will prospectively
evaluate the prognostic significance of pan-cytokeratin/
CXCR4-positive cells, and determine the mechanisms
involved in the regulation of CXCR4 expression on tumor
cells.
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